Best Japanese Companies For 2017

The optimal retirement age may be a bit sooner than expected for scores of Millennials. According to a recent report from Merrill Edge, Millennials are planning to leave the workforce when they attain a particular savings goal or a milestone in their finances. By contrast, members of older generations planned to retire only when they reached a certain age or their health prevented them from continuing to work.

The results were encouraging to see, as retirement is changing, and younger generations, Millennials in particular, are recognizing the need to have a different approach to make sure theyll be able to afford their later years, says Aron Levine, head of Merrill Edge.

Best Japanese Companies For 2017: Brown(n)

N Brown Group plc operates as an Internet and catalogue home shopping company in the United Kingdom. The company principally offers womenswear, menswear, footwear, household, and electrical products, as well as provides insurance services. It also operates in the Republic of Ireland, Germany, and the United States. The company was founded in 1859 and is based in Manchester, the United Kingdom.

Advisors’ Opinion:

  • [By Alex Jordon]

    He already owns a good chunk of NetSuite (N), whose revenue grew 35% last quarter, beating earnings estimates by $0.03 a share. Ellison’s been profiting from the cloud while dismissing its significance. With the Salesforce agreement his company is, too. (Fool)

Best Japanese Companies For 2017: Buffalo Wild Wings Inc.(BWLD)

Buffalo Wild Wings, Inc. engages in the ownership, operation, and franchise of restaurants in the United States. The company provides quick casual and casual dining services, as well as serves bottled beers, wines, and liquor. As of July 26, 2011, it had 773 Buffalo Wild Wings locations in 45 states in the United States, as well as in Canada. The company was founded in 1982 and is headquartered in Minneapolis, Minnesota.

Advisors’ Opinion:

  • [By CNBC]

    Tony Tribble, Invision/AP Forget about Bloomin’ Onions or boneless wings, for many consumers, the choice of where to dine often comes down to a different factor: which restaurant has the best booze. “Alcoholic beverages can be a key driver of traffic, differentiation, and loyalty,” said David Decker, president of Consumer Edge Insight. According to the firm, two factors that keep customers coming back are “selection” and “pricing.” Consumer Edge Insight recently surveyed restaurant customers to find out which casual-dining spots generated the most loyalty with their alcoholic beverages. Taking the top spot for “selection” was Buffalo Wild Wings (BWLD), with 29 percent of those surveyed saying they were “most likely to visit it most often due to its good selection of alcoholic beverages.” Applebee’s (DIN) took the second spot, with 24 percent, and Outback Steakhouse (BLMN) and T.G.I. Friday’s tied for third place with 22 percent each. Prices also keep customers coming back to Buffalo Wild Wings. When asked which casual-dining brand they were “most likely to visit most often due to its good prices of alcoholic beverages,” Buffalo Wild Wings came out on top with 30 percent. Chili’s (EAT) was No. 2 at 23 percent, and Ruby Tuesday (RT) was third with 22 percent. Buffalo Wild Wings has always made alcohol a part of its experience, even making it part of its tagline: “Wings.Beer.Sports.” The chain is the No. 1 account for more than 50 different beer brands and recently launched Game Changer, a new beer in a partnership with Redhook Brewery. Priced between cheaper domestic lagers and pricier craft beers, Game Changer became the fourth-most-popular draft beer at company-owned locations within two weeks of its release. “Among casual-dining restaurants, Buffalo Wild Wings is seeing the greatest positive effect in terms of building customer loyalty with its alcohol offerings,” Decker said. “There are many steps other restaurants can take to improve their alcoho

  • [By Lisa Levin]

    Shares of Buffalo Wild Wings (NASDAQ: BWLD) were down 12 percent to $127.89 as the company reported weaker-than-expected results for its first quarter on Tuesday.

Top 10 Restaurant Companies To Buy Right Now: Yingli Green Energy Holding Company Limited(YGE)

 

Yingli Green Energy Holding Company Limited, together with its subsidiaries, designs, develops, markets, manufactures, sells, and installs photovoltaic (PV) products in the Peoples Republic of China and internationally. The company offers polysilicon ingots and blocks, polysilicon wafers, PV cells, PV modules, and integrated PV systems; and develops and operates solar projects. It primarily sells its PV modules to distributors, wholesalers, power plant developers and operators, and PV system integrators under the brand names Yingli and Yingli Solar. Yingli Green Energy Holding Company Limited was founded in 1998 and is headquartered in Baoding, the Peoples Republic of China.

Advisors’ Opinion:

  • [By Monica Gerson]

    Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) is expected to post a quarterly loss at $1.48 per share on revenue of $372.30 million.

    Ameren Corp (NYSE: AEE) is estimated to post its quarterly earnings at $0.38 per share on revenue of $1.51 billion.

Best Japanese Companies For 2017: Progenics Pharmaceuticals Inc.(PGNX)

Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.

Azedra

Azedra is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands. The Company has completed enrollment in pivotal Phase IIb clinical trial under Special Protocol Assessment (SPA).

1404 (trofolastat)

The Company’s 1404 (trofolastat) is a technetium-99m labeled small molecule, which binds prostate specific membrane antigen (PSMA) and is used as an imaging agent to diagnose and detect localized prostate cancer, as well as soft tissue and bone metastases. The Company has completed a global multi-centered Phase II study assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer and initiated a multi-center, open-label Phase III trial to determine the sensitivity and specificity of 1404 to correctly identify whether or not patients hav e clinically prostate cancer

PyL ((18F) DCFPyL)!

The Company’s PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine. The Company’s studies show the uptake of PyL is high in sites of putative metastatic lesions and primary tumors, suggesting the potential for high sensitivity in detecting prostate cancer.

1095

The Company’s 1095 is a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule, which is designed to deliver a dose of radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The Company focuses on initiating a Phase I clinical study.

PSMA ADC

PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer. The Company’s Phase II, multicenter clinical tr ial to assess the safety, tolerability and anti-tumor activity of PSMA ADC, has been completed in both the chemotherapy refractory and chemotherapy naive patients with metastatic castration-resistant prostate cancer (mCRPC).

Relistor

The Company’s Relistor is used as a treatment for Opioid-Induced Constipation (OIC), which decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. Relistor-Subcutaneous injection is engaged in the treatment of OIC in patients with non-cancer pain, and is marketed in the United States. Relistor-Oral has completed Phase III clinical trials.

PRO 140

The Company’s PRO 140 is a humanized IgG4 monoclonal antibody directed against C-C chemokine receptor type 5 (CCR5), a molecular portal that human immunodeficiency virus (HIV) uses to enter T-cells. PRO 140 blocks the predominant HIV subtype (R5) entry i nto T-cells by masking this required co-receptor, CCR5. PRO ! 140 has b! een the subject of over seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects.

The Company competes with Merck & Co., Inc., Sucampo Pharmaceuticals, Inc., Shionogi & Co., Theravance, Inc., Johnson & Johnson, Medivation, Inc., Bayer HealthCare Pharmaceuticals Inc. and Aytu Bioscience Inc.

Advisors’ Opinion:

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).